-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2022, the interest of securities companies in investigating listed companies in the pharmaceutical and biological industry has not diminished.
Among them, the Chinese medicine sector, which has performed strongly since the end of 2021, has become the focus of institutional attention.
Many Chinese medicine companies have recently released relevant investor relations activities.
Record sheets, including Conba, Yiling Pharmaceutical, Xintian Pharmaceutical,
etc.
On January 21, Conba released a record form of investor relations activities.
The company accepted a survey on January 21, 2022 by one institutional unit, and the type of institution was other
.
From the perspective of main communication issues, institutions mainly focus on the company's strategic direction and future growth points
.
In response to the issue of strategic direction, Kang Enbei said that the company's existing product business structure is based on modern traditional Chinese medicine and botanical medicine, and is supported by characteristic chemical medicines including APIs and preparations, as well as functional health products
.
At this stage, the company will not make major adjustments to the existing product business structure, nor will it divest chemical products from the company's existing business system
.
As for the future growth point, Kang Enbei believes that with the gradual elimination of the drag factors on performance in 2021, and after the disposal of some inefficient and invalid assets and the full provision for asset impairment, the company is taking a light-weight approach.
The battle situation has entered a new round of development
.
The growth in 2022 is something to look forward to, driven by the two-wheel drive of endogenous growth and extensional M&A
.
Yiling Pharmaceutical released a record of investor relations activities on January 20, and the company received surveys from 44 institutions on January 19, 2022
.
During the research activities, the company's future sales growth momentum of Lianhua Qingwen, the overseas listing and sales of Lianhua Qingwen, the next potential sales varieties, and the impact of centralized procurement of Chinese patent medicines on the company have received attention from institutions
.
Regarding the centralized procurement of proprietary Chinese medicines, the company stated that it will seriously and actively participate in the centralized procurement
.
Xintian Pharmaceutical released a record form of investor relations activities on January 7, and the company received 46 institutional investigations on January 6, 2022
.
In the research and interaction link, the company's product price increase ideas, R&D layout and R&D investment direction are more concerned by institutions
.
Regarding the issue of product price increase, Xintian Pharmaceutical stated that the company's OTC product prices are relatively market-oriented; the company's product gross profit is high, whether to raise prices will fully consider product power, brand power and brand cultivation, product cost, product upgrade, market share, patient acceptance and other factors, and then make corresponding decisions
.
In terms of R&D layout and investment, the company stated that TCM research runs through all stages of new TCM drug discovery, R&D, production, and re-evaluation after listing, forming a product that meets the requirements of national drug laws and regulations, conforms to the rules of TCM R&D, and has its own characteristics.
development system
.
At present, the company's Longqin Pengqiang Shu Granules, Shuyutong Granules, Ku'e Jieyin Capsules and other three varieties have completed phase III clinical research, and will gradually submit applications for marketing authorization in light of the actual situation; For the research on the classic traditional Chinese medicine prescriptions of the respiratory department, it is planned to submit applications for marketing authorization after the relevant departments release the key information of the corresponding prescriptions; continue to carry out the company's key varieties of Kuntai Capsules, Ningmitai Capsules, Sophora Radix Gel, Prunella Prunella Oral Liquid clinical medical research and secondary development of related products
.
Among them, the Chinese medicine sector, which has performed strongly since the end of 2021, has become the focus of institutional attention.
Many Chinese medicine companies have recently released relevant investor relations activities.
Record sheets, including Conba, Yiling Pharmaceutical, Xintian Pharmaceutical,
etc.
On January 21, Conba released a record form of investor relations activities.
The company accepted a survey on January 21, 2022 by one institutional unit, and the type of institution was other
.
From the perspective of main communication issues, institutions mainly focus on the company's strategic direction and future growth points
.
In response to the issue of strategic direction, Kang Enbei said that the company's existing product business structure is based on modern traditional Chinese medicine and botanical medicine, and is supported by characteristic chemical medicines including APIs and preparations, as well as functional health products
.
At this stage, the company will not make major adjustments to the existing product business structure, nor will it divest chemical products from the company's existing business system
.
As for the future growth point, Kang Enbei believes that with the gradual elimination of the drag factors on performance in 2021, and after the disposal of some inefficient and invalid assets and the full provision for asset impairment, the company is taking a light-weight approach.
The battle situation has entered a new round of development
.
The growth in 2022 is something to look forward to, driven by the two-wheel drive of endogenous growth and extensional M&A
.
Yiling Pharmaceutical released a record of investor relations activities on January 20, and the company received surveys from 44 institutions on January 19, 2022
.
During the research activities, the company's future sales growth momentum of Lianhua Qingwen, the overseas listing and sales of Lianhua Qingwen, the next potential sales varieties, and the impact of centralized procurement of Chinese patent medicines on the company have received attention from institutions
.
Regarding the centralized procurement of proprietary Chinese medicines, the company stated that it will seriously and actively participate in the centralized procurement
.
Xintian Pharmaceutical released a record form of investor relations activities on January 7, and the company received 46 institutional investigations on January 6, 2022
.
In the research and interaction link, the company's product price increase ideas, R&D layout and R&D investment direction are more concerned by institutions
.
Regarding the issue of product price increase, Xintian Pharmaceutical stated that the company's OTC product prices are relatively market-oriented; the company's product gross profit is high, whether to raise prices will fully consider product power, brand power and brand cultivation, product cost, product upgrade, market share, patient acceptance and other factors, and then make corresponding decisions
.
In terms of R&D layout and investment, the company stated that TCM research runs through all stages of new TCM drug discovery, R&D, production, and re-evaluation after listing, forming a product that meets the requirements of national drug laws and regulations, conforms to the rules of TCM R&D, and has its own characteristics.
development system
.
At present, the company's Longqin Pengqiang Shu Granules, Shuyutong Granules, Ku'e Jieyin Capsules and other three varieties have completed phase III clinical research, and will gradually submit applications for marketing authorization in light of the actual situation; For the research on the classic traditional Chinese medicine prescriptions of the respiratory department, it is planned to submit applications for marketing authorization after the relevant departments release the key information of the corresponding prescriptions; continue to carry out the company's key varieties of Kuntai Capsules, Ningmitai Capsules, Sophora Radix Gel, Prunella Prunella Oral Liquid clinical medical research and secondary development of related products
.
